anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: invention refers to pharmaceutics. Production of ginkgo biloba extract with low content of 4'-O-methylpyridoxine and/or biflavones involves the stages as follows: (a) production of ginkgo biloba solution in a solvent, (b) application of the solution on an adsorbing resin chosen from styrene copolymer and divinylbenzene or bromated styrene copolymer and divinylbenzene, and elution of the purified extract from adsorbing resin by a solvent, with biflavones kept on the adsorbing resin and/or (c) application of the solution on a strong-acid ion exchanger and elution of the purified extract from the ion exchanger with a solvent with 4'-O-methylpyridoxine kept on the ion exchanger. The solvent at the stages (a), (b) and (c) is independently chosen from aqueous alkanole containing 1-3 carbon atoms, and aqueous ketone containing 3-6 carbon atoms, and (d) concentration and drying of the extract solution to prepare the dry extract with 4'-O-methylpyridoxine not exceeding 20 w.f. and/or biflavone content not exceeding 25% of content in the original extract. Ginkgo extract is applied for making a medical product for treatment of dementia and its symptoms and/or cerebral and peripheral blood circulation disturbances, or a food additive. The medical product or food additive for treatment of dementia and its symptoms and/or cerebral and peripheral blood circulation disturbances is characterised by ginkgo extract content. ^ EFFECT: invention allows producing extract with low content of 4'-O-methylpyridoxine and/or biflavones. ^ 11 cl, 2 tbl, 6 ex
Part B is a repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions. This information will provide insight into whether the biomarker effects change over time on repeat dosing and any potential differences observed between single and repeat doses.
After Step 2, and after follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage (RFCA, Step3). Patients will receive catheter ablation of AF, up to patients' willingness. After follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will go to next group/stage (SAFE PAF-SND II).
Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia. The study may enroll up to 10 participants looking for improvement in their hair loss. All participants will have biopsy-proven alopecia before enrollment. There will be two treatment arms with 5 participants in the androgenetic alopecia arm and 5 participants in the scarring alopecia arm. Multiple treatment areas of the scalp may be performed. Each subject will receive up to three treatments. Follow-up visits are planned for months 6, 9, 12, and 15. Standardized photography, hair density measurement of the treated scalp areas will be recorded Pre and Post Treatment at each visit. Measurement outcomes will be compared to baseline. During the initial visit, subjects who meet the study's eligibility criteria will receive the first treatment after signing informed consent form.

For this study, the investigators will use non-ablative HALO laser (1470nm) (Sciton). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The laser creates controlled zones of coagulation within the dermis. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment procedure will consist of topical anesthetic then cleaning of the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide. The U.S. Food and Drug Administration (FDA) has approved the 1470 nm laser for dermatologic purposes.

The follow up phase will consist of clinical assessments including before and after photographs graded by blinded observers and hair density evaluation using Canfield HairMetrix ® device. Subjects are instructed to inform clinical staff after the treatment if they experience any adverse events and will complete patient questionnaires, pain score, and self-assessment of hair growth.
PURPOSE: Provided are an aqueous ophthalmic composition containing vitamin E or ester thereof as an active ingredient, sorbic acid or salts thereof as a preservative, and surfactant, which is useful for treatment of various eye diseases, especially for cataract. CONSTITUTION: The aqueous ophthalmic composition contains vitamin E or ester thereof as an active ingredient, sorbic acid or salts thereof as a preservative, and a surfactant. A concentration of vitamin E or ester thereof is 0.1 - 10%. A concentration of sorbic acid or salts thereof is 0.1 - 1.0%. The amount of the surfactant is 0.2 - 30 times an amount of the vitamin E or ester thereof. The aqueous ophthalmic composition further contains edetic acid or salts thereof as an increasing agent for preservative effect.
Patients randomized to the intervention arm will have the results of the Cuff Leak Test (CLT) (whether failed or passed) communicated to the treating physician; the treating physician will decide whether to proceed with extubation or not based on the CLT results. It is at the discretion of the treating physician to provide corticosteroids (4-5 mg of intravenous dexamethasone every six hours for up to 24 hours, with the last dose given one hour preceding extubation) and/or delay extubation by 24 hours should the patient fail the CLT.
PROBLEM TO BE SOLVED: To obtain a composition for an inflammation suppressing agent, effective for suppressing allergic inflammation and non-allergic inflammation and having high utility by using a precipitate obtained by adding an organic solvent to a cultured liquid of a specific actinomycete. SOLUTION: An organic solvent is added to a cultured liquid of Streptomyces kanamyceticus belonging to actinomycete and the obtained precipitate is used as an active component of the objective composition. Preferably, the precipitate is further subjected to gel-filtration column chromatography and the fraction having a molecular weight of 1,000,000-10,000,000 in terms of dextran is used as the active component. The actinomycete Streptomyces kanamyceticus is easily available e.g. as a strain (JCM4433) stocked by the Institute of Physical and Chemical Research. The administration dose of the inflammation suppressing agent is about 1ng/kg to 1g/kg in the case of a composition containing the precipitate as the active component and about 0.01ng/kg to 10mg/kg in the case of a composition containing the gel-filtrated fraction as the active component.  The amount of the active component in the composition is about 0.1-50wt.%.
After randomization, patients in this arm received LCZ696 (Sacubitril/Valsartan) twice daily and matching placebo of Enalapril depending on the patient's previous ACEI/ARB dose (enalapril equivalent dose) for 2 weeks. Patients could start study medication at dose level 1 (24 mg/26 mg LCZ), 2 (49 mg/51 mg LCZ) or 2a (49 mg/51 mg LCZ) or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 97 mg/103 mg bid LCZ696(sacubitril/valsartan) and matching placebo, provided no safety and tolerability issues arised during uptitration.
Rice (Oryza sativa) produces phenolamides and diterpenoids as major phytoalexins. Although the biosynthetic pathways of phenolamides and diterpenoids in plants have been revealed, knowledge of their accumulation regulatory mechanisms remains limited, and, in particular, no co-regulatory factor has been identified to date. Here, using a combined co-expression and evolutionary analysis, we identified the basic helix-loop-helix (bHLH) transcription factor OsbHLH5 as a positive bifunctional regulator of phenolamide and diterpenoid biosynthesis in rice. Metabolomic analysis revealed that OsbHLH5 significantly increased the content of phenolamides (such as feruloyl tryptamine (Fer-Trm) and p-coumaroyl tyramine (Cou-Tyr)) and diterpenoid phytoalexins (such as momilactones A, momilactones B) in the overexpression lines, while their content was reduced in the OsbHLH5 knockout lines. Gene expression and dual-luciferase assays revealed that OsbHLH5 activates phenolamide biosynthetic genes (including putrescine hydroxycinnamoyltransferase 3 (OsPHT3), tyramine hydroxycinnamoyltransferases 1/2 (OsTHT1/2), and tryptamine benzoyltransferase 2 (OsTBT2)) as well as diterpenoid biosynthetic genes (including copalyl diphosphate synthase 4 (OsCPS4) and kaurene synthase-like 4/7/10/11 (OsKSL4/7/10/11)). Furthermore, we have demonstrated that OsbHLH5 is induced by jasmonic acid (JA), while pathogen inoculation assays indicated that the overexpression of OsbHLH5 in transgenic rice plants leads to enhanced resistance to Xanthomonas oryzae pv. oryzae (Xoo). Overall, we have identified a positive regulator of phenolamide and diterpenoid biosynthesis and have demonstrated that biotic stress induces phytoalexin accumulation partly in an OsbHLH5-dependent manner, providing new insights into the metabolic interactions involved in pathogen response and offering valuable gene resources for the development, through genetic improvement, of new rice varieties that are resistant to diseases.
PURPOSE:To obtain an antitumor agent having excellent activity and low toxicity, comprising a specific polysulfide compound as an active ingredient. CONSTITUTION:A polysulfide compound shown by formula I [R1 is CH3, CH2= CHCH2, or C2H5OCO(CH2)3; R2 is SCH2CH=CH2 or group shown by formula II (q is 0 or 1; r is 0-2; R3 is alkyl, benzyl, etc.); p is 1-2] is blended with ordinary drug auxiliary components and pharmaceutically manufactured by a conventional procedure to give the aimed substance. The substance can be made into a dosage form such as powder, granule, capsule, injection, ointment, aerosol, solution, etc. A daily dose is 10mg-10g, preferably 50mg-5g per adult in oral administration or intravenous and administered dividedly one - several times. In parenteral administration, a dose is properly 1-1,000mug/mg, preferably 20-200mug/ml based on an external preparation of the compound shown by the formula I.
Prolonged exposure to hypoxic and low-pressure environments leads to structural remodeling and functional abnormalities in the cardiovascular, respiratory, and hematological systems of high-altitude populations. This elevates the risk of postoperative complications, particularly in patients undergoing orthopedic surgery, significantly impacting their recovery and quality of life. This study will focus on orthopedic surgery patients from high-altitude regions. Using smart wearable devices and other monitoring tools, comprehensive perioperative dynamic data of participants, including heart rate, heart rate variability, oxygen saturation, respiratory rate, sleep quality, activity levels, stress index, and other relevant indicators will be collected. Regular follow-ups will be conducted to evaluate postoperative recovery and monitor the incidence of perioperative complications. Additionally, perioperative data such as electronic medical records, laboratory test results, ECG waveforms, echocardiography, chest CT images, and other pertinent records will be also collected. Through that, this study aims to establish a follow-up cohort of orthopedic surgery patients from high-altitude regions.
The invention discloses a pure traditional Chinese medicine preparation for prompting rapid growth of pigs. Each part of preparation comprises fried astragalus root, codonopsis pilosula nnannf, roasted bighead atractylodes rhizome, angelica, radix rehmanniae preparata, cimicifugae foetidae, spina date seed, roasted hovenia dulcis, bunge cherry seed, desertliving cistanche, platycodon grandiflorum, fructus cannabis, peach kernel, almond, pinenut kernel, chrysoidine and radix trichosanthis. The invention further discloses a preparation method and an application method of the traditional Chinese medicine preparation. The traditional Chinese medicine preparation has the functions of tonifying qi, engendering liquid, lubricating the intestines, prompting digestion, calming and soothing the nerves, the traditional Chinese medicine preparation mainly improves the digestion function of animal bodies on feed to increase the nutrient substances absorbed by the animal bodies, reduces the movements of the animals and locates the animals at quiet and comfortable states to reduce energy consumption and make more nutrient substances in the animal bodies to participate in an anabolic reaction in the animal bodies so as to reduce the feed conversion ratio while improving the growth speed of the pigs. The application method of the preparation is simple and convenient to operate and is free of unfavorable stimulation on the pigs. The preparation is applied in the application method to ensure an excellent treatment effect and is an excellent pure traditional Chinese medicine preparation for prompting pig growth.
Pain management for total knee replacement (TKR) patients has evolved rapidly over the previous decade. The most recent advances in anesthesia include peripheral nerve blockade, which offers the promise of earlier postoperative mobilization in addition to effective pain relief. The rapidity with which these advancements have been adopted seems to have outpaced the science to support them. The result has been the institution of countless combinations of perioperative pain management strategies in centers nationwide with little standardization, consistency, or objective evidence. The extent to which these various strategies achieve safe and effective perioperative pain control or functional preservation remains poorly defined. This prospective randomized control trial will aim to identify meaningful patient-centric outcome measures, differentiate from among three perioperative TKR anesthetic and analgesic strategies, and provide a template for interdisciplinary collaboration among orthopedic surgeons, anesthesiologists, physical therapists, and patients. With the knowledge gained further study will continue to refine the most optimal early pain control protocol.

All primary TKR patients undergoing surgery at the Medical University of South Carolina who are able to receive spinal anesthesia will be randomized prior to surgery to one of three forms of lower limb nerve blockade: 1) Continuous femoral nerve catheter plus single injection sciatic nerve block, 2) Adductor canal catheter plus selective tibial nerve block, 3) Adductor canal catheter alone. All patients will receive additional standardized pain medications as well as early mobilization with physical therapy. The primary outcome measure will be postoperative visual analog pain scale (VAS), with secondary measures to include validated patient-reported outcome measures, objective functional measures (timed-up-and-go (TUG), patient satisfaction scores, length of stay, discharge disposition, and complications. The investigators plan to enroll approximately 90 patients. This will allow us to reach our randomization goal of at least 75 patients while taking into account withdrawals. The 75 patients will be randomized into the three treatment three treatment arms over a 6-month recruitment period, with a 3 month follow-up for patient reported outcome and satisfaction data. A focus group will facilitate patient engagement and provide information for generation of a preference survey to guide future study design.
BACKGROUND: This study aimed to develop and validate a model based on the collagen signature and systemic immune-inflammation index to predict prognosis in rectal cancer patients who underwent neoadjuvant treatment.
METHODS: Patients with rectal cancer who had residual disease after neoadjuvant treatment at two Chinese institutions between 2010 and 2018 were selected, one used as a training cohort and the other as a validation cohort. In total, 142 fully quantitative collagen features were extracted using multiphoton imaging, and a collagen signature was generated by least absolute shrinkage and selection operator Cox regression. Nomograms were developed by multivariable Cox regression. The performance of the nomograms was assessed via calibration, discrimination and clinical usefulness. The outcomes of interest were overall survival and disease-free survival calculated at 1, 2 and 3 years.
RESULTS: Of 559 eligible patients, 421 were selected (238 for the training cohort and 183 for the validation cohort). The eight-collagen-features collagen signature was built and multivariable Cox analysis demonstrated that it was an independent prognostic factor of prognosis along with the systemic immune-inflammation index, lymph node status after neoadjuvant treatment stage and tumour regression grade. Then, two nomograms that included the four predictors were computed for disease-free survival and overall survival. The nomograms showed satisfactory discrimination and calibration with a C-index of 0.792 for disease-free survival and 0.788 for overall survival in the training cohort and 0.793 for disease-free survival and 0.802 for overall survival in the validation cohort. Decision curve analysis revealed that the nomograms could add more net benefit than the traditional clinical-pathological variables.
CONCLUSIONS: The study found that the collagen signature, systemic immune-inflammation index and nomograms were significantly associated with prognosis.
The recent pandemic caused by the SARS-CoV-2 virus and the associated mental health complications have renewed scholarly interest in the relationship between viral infections and the development of mental illnesses, a topic that was extensively discussed in the previous century in the context of other viruses, such as influenza. The most probable and analyzable mechanism through which viruses influence the onset of mental illnesses is the inflammation they provoke. Both infections and mental illnesses share a common characteristic: an imbalance in inflammatory factors. In this study, we sought to analyze and compare cytokine profiles in individuals infected with viruses and those suffering from mental illnesses. The objective was to determine whether specific viral diseases can increase the risk of specific mental disorders and whether this risk can be predicted based on the cytokine profile of the viral disease. To this end, we reviewed existing literature, constructed cytokine profiles for various mental and viral diseases, and conducted comparative analyses. The collected data indicate that the risk of developing a specific mental illness cannot be determined solely based on cytokine profiles. However, it was observed that the combination of IL-8 and IL-10 is frequently associated with psychotic symptoms. Therefore, to assess the risk of mental disorders in infected patients, it is imperative to consider the type of virus, the mental complications commonly associated with it, the predominant cytokines to evaluate the risk of psychotic symptoms, and additional patient-specific risk factors.
The SABRINA study [NCT01200758] was a randomized, two-stage, open-label, multicenter study that enrolled a total of 410 patients with previously untreated, CD20-positive follicular lymphoma of Grade 1, 2 or 3a requiring therapy. The study design is identical in stage 1 and 2. Patients were randomized (1:1) to receive either a rituximab product by intravenous infusion 375 mg/m2 for 8 cycles or 1 cycle of a rituximab product by intravenous infusion 375 mg/m2 followed by 7 cycles of RITUXAN HYCELA 1,400 mg/23,400 Units (1,400 mg rituximab and 23,400 Units hyaluronidase human) both every 3 weeks in combination with a total of 6–8 cycles of CHOP or 8 cycles of CVP chemotherapy. Patients underwent interim staging after 4 cycles. Patients who received R-CHOP and achieved a CR, CRu, PR or SD at the interim assessment could receive either 4 more cycles of R-CHOP or 2 cycles of R-CHOP followed by 2 cycles of monotherapy with rituximab product or RITUXAN HYCELA depending on randomization arm (i.e., a total of 8 cycles of rituximab product or RITUXAN HYCELA). Patients with at least a PR after combination treatment with chemotherapy continued with single agent maintenance treatment administered every 8 weeks for 24 months with rituximab product or RITUXAN HYCELA as per their randomization (i.e., total of 12 cycles of maintenance treatment).

Randomization was stratified by: underlying chemotherapy backbone (CHOP vs CVP), Follicular Lymphoma International Prognostic Index (FLIPI) (low-risk vs. intermediate-risk vs. high-risk), and region (Europe and North America vs. South and Central America vs Asia).

The main outcome measure for Stage 1 was the estimated ratio of observed rituximab serum Ctrough SC/Ctrough IV at Cycle 7 of combination treatment with chemotherapy every 3 weeks. The main outcome measure for Stage 2 was the investigator-assessed ORR consisting of CR, CRu, and PR at the completion of combination treatment with chemotherapy. Additional outcome measures were CRR (CR and CRu) at the end of completion of combination treatment with chemotherapy, ORR and CRR at the end of completion of maintenance treatment, and time-to-event endpoints (progression-free survival (PFS), and overall survival (OS)).

Of all randomized patients, the median age was 57 years (range: 28 to 86), 53% were female, and 86% were White. The median BSA was 1.83 m2. 45% had high risk or 34% had intermediate risk FLIPI score, and 54% had Ann Arbor Stage IV disease. Ninety percent of patients completed all 8 cycles of combination treatment with chemotherapy, and 70% of patients completed 20 cycles of both combination and maintenance treatment. Median treatment duration was 27.1 months in both groups. The median number of cycles received was 20 in both groups.

The pharmacokinetic results for the primary endpoint in Stage 1, rituximab Ctrough at Cycle 7 (i.e., 21 days after Cycle 7 rituximab administration), demonstrated that RITUXAN HYCELA 1,400 mg/23,400 Units was non-inferior compared with rituximab at 375 mg/m2 in patients receiving combination treatment with chemotherapy [see Clinical Pharmacology (12.3)]. The efficacy results are presented in Table 6.
Data will be collected through an online questionnaire consisting of four parts. Part 1 will gather socio-demographic data using nine items. Part 2 will utilize the Antifat Attitudes Questionnaire (AFA), developed by Crandall in 1994. The questionnaire, comprising 13 items, will assess three subscales:1. "Dislike" measuring explicit antipathy toward fat individuals.2. "Fear of Fat" measuring personal concerns about weight or becoming overweight.3. "Willpower" measuring beliefs about personal control over being overweight. Participants will rate items on a 10-point Likert scale, with higher scores indicating greater anti-fat bias. Part 3 will include a questionnaire developed by Bocquier in 2005 to explore weight stigma among physicians, consisting of 12 items. Participants will rate items on a 6-point Likert scale, with higher scores indicating stronger weight stigma. Part 4 will investigate the therapeutic approach of orthopedic surgeons to patients with obesity using five items. Participants will items on a 6-point Likert scale, with higher scores indicating a stronger preference for a conservative approach.